Advances in Interventional Oncology for Hepatocellular Carcinoma
4 affiliations
- 1Interventional Radiology Division, Imaging Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
- 2School of Radiology, Institute of Medicine, Suranaree University of Technology, Nakhon Ratchasima 30000, Thailand
- 3Medical College, Faculty of Health Sciences, Aga Khan University, Karachi 74800, Pakistan
- 4Department of Radiology, University of Michigan, Ann Arbor, MI 48109, USA
Abstract
Locoregional therapies are used across the hepatocellular carcinoma (HCC) treatment spectrum, including for curative treatment of small tumors, as bridging or downstaging therapy before liver transplant, for treatment of intermediate-stage disease, and as part of combination treatment with systemic therapy in selected patients. This narrative review summarizes recent developments in transarterial radioembolization (TARE), transarterial chemoembolization (TACE), and percutaneous ablation techniques and separates established clinical advances from early investigational work. The strongest evidence supports personalized TARE dosimetry and radiation segmentectomy, selective TACE with reassessment before repeat treatment, and image-guided thermal ablation with objective margin assessment. Phase 3 trials of TACE combined with antiangiogenic and immune checkpoint therapy demonstrated improved progression-free survival in selected patients with unresectable, nonmetastatic HCC, although the survival benefit of these combinations so far extends only to progression-free survival, and the best treatment sequence remains to be defined. Histotripsy, pulsed electric-field ablation, electrochemotherapy, cryoablation, high-intensity focused ultrasound, imageable or alternative radioembolic microspheres, new embolic agents, robotics, and artificial intelligence remain at different stages of clinical development. Most supporting data are derived from single-arm studies, retrospective cohort studies, trials in mixed liver-tumor populations, or studies in preclinical models. Treatment selection should account for tumor burden and location, liver function, portal hypertension, vascular invasion, transplant candidacy, available alternatives, local expertise, and patient preferences. Future studies should focus on durable local control, preservation of liver function, quality of life, transplant eligibility, overall survival, and cost.
Related
- Peri-interventional neutrophil extracellular traps and immune surveillance in hepatocellular carcinoma: mechanisms, biomarkers, and recurrence after liver resection or thermal ablation
- Precision surgical oncology for hepatocellular carcinoma
- Relationships among heart rate variability, sleep disturbances, and fatigue in patients undergoing interventional therapy for hepatocellular carcinoma.
- Interventional strategies for inferior phrenic artery management in yttrium‑90 selective internal radiation therapy for hepatocellular carcinoma: A single‑center retrospective study
- Multimodal AI in Hepatocellular Carcinoma: Bridging Diagnosis, Therapy and Prognosis Toward Precision Oncology.
BibTeX
@article{gadani2026advances,
title = {{Advances in Interventional Oncology for Hepatocellular Carcinoma}},
author = {Sameer Gadani and Edwin Chou and Jirapa Chansangrat and Hashim Salar and Baljendra Kapoor},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18203319},
url = {https://www.mdpi.com/2072-6694/18/20/3319},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Advances in Interventional Oncology for Hepatocellular Carcinoma
AU - Sameer Gadani
AU - Edwin Chou
AU - Jirapa Chansangrat
AU - Hashim Salar
AU - Baljendra Kapoor
PY - 2026
DA - 2026/10/01
JO - Cancers
DO - 10.3390/cancers18203319
UR - https://www.mdpi.com/2072-6694/18/20/3319
AB - Locoregional therapies are used across the hepatocellular carcinoma (HCC) treatment spectrum, including for curative treatment of small tumors, as bridging or downstaging therapy before liver transplant, for treatment of intermediate-stage disease, and as part of combination treatment with systemic therapy in selected patients. This narrative review summarizes recent developments in transarterial radioembolization (TARE), transarterial chemoembolization (TACE), and percutaneous ablation techniques and separates established clinical advances from early investigational work. The strongest evidence supports personalized TARE dosimetry and radiation segmentectomy, selective TACE with reassessment before repeat treatment, and image-guided thermal ablation with objective margin assessment. Phase 3 trials of TACE combined with antiangiogenic and immune checkpoint therapy demonstrated improved progression-free survival in selected patients with unresectable, nonmetastatic HCC, although the survival benefit of these combinations so far extends only to progression-free survival, and the best treatment sequence remains to be defined. Histotripsy, pulsed electric-field ablation, electrochemotherapy, cryoablation, high-intensity focused ultrasound, imageable or alternative radioembolic microspheres, new embolic agents, robotics, and artificial intelligence remain at different stages of clinical development. Most supporting data are derived from single-arm studies, retrospective cohort studies, trials in mixed liver-tumor populations, or studies in preclinical models. Treatment selection should account for tumor burden and location, liver function, portal hypertension, vascular invasion, transplant candidacy, available alternatives, local expertise, and patient preferences. Future studies should focus on durable local control, preservation of liver function, quality of life, transplant eligibility, overall survival, and cost.
SN - 2072-6694
ER -